magle chemoswed.

Press Release
July 30, 2026

Magle Chemoswed Holding AB (publ) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028 and its senior secured bonds 2026/2028

On 13 July 2026, Magle Chemoswed Holding AB (publ) (the "Company") announced that it had initiated a written procedure in relation to its (i) senior secured bonds 2025/2028 with ISIN SE0025197403 (the "Initial Bonds") and (ii) senior secured bonds 2026/2028 with ISIN SE0029503697 (the "Bonus Bonds" and together with the Initial Bonds, the "Existing Bonds") (the "Written Procedure"), to request the holders of the Existing Bonds to vote in favour of certain waivers and requests in order to implement the New Structure (as defined in the notice of the Written Procedure) by way of consenting to the proposals set out in the notice of the Written Procedure. The full details of the proposals are set out in the notice of the Written Procedure.

A sufficient number of holders of Existing Bonds participated in the Written Procedure and the requisite majority voted in favour of the proposals. The Company is therefore pleased to announce the successful completion of the Written Procedure.

The Company will initiate the implementation of the contemplated amendments and waivers as set out in the notice of Written Procedure and will update the market with a time plan for the implementation steps once available. Any holder of Existing Bonds who, in accordance with the instructions set out in the notice of the Written Procedure, has subscribed for Super Senior Bonds (as defined in the notice of the Written Procedure) will be contacted directly.

Contacts

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on **www.maglechemoswed.com** and **www.maglegroup.com** and **www.maglebiopolymers.com**

Redeye Nordic Growth AB is the company's Certified Adviser.

Attachments

Magle Chemoswed Holding AB (publ) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028 and its senior secured bonds 2026/2028

Agneslundsvägen 27, 212 15 Malmö , Sweden +46 (0)40 38 33 00 info@maglechemoswed.com maglechemoswed.com